Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

MMJ Recs

MAY 9, 2024

As such, we provide you with a comprehensive guide for veterans using medical cannabis and the various aspects of it, including its usage, accessibility, legal considerations, healthcare options, and available resources. Navigating the complexities surrounding the Veterans Administration and medical cannabis can be daunting.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public . The full statement.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

JULY 24, 2021

At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. “At At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JANUARY 12, 2022

Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We The Maya platform empowers psychedelic researchers, providers, and participants to collectively chart psychedelic best practices.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Partnership being developed with leading UK institutions to accelerate psychedelic research and develop new models of mental health care in the UK. LONDON, Aug.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

NORML

JANUARY 4, 2019

Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution. Legislation is pending, HB 350, to expand medical cannabis access. NH resident? GA resident?

Legislation 126

Legislation Clinical Trials Research and Development Access 126

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. But if that doctor has access to information from 40,000 patients it’s a different story. The Upshot.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JULY 1, 2021

The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is engaged in a three-year initiative to examine the ethical, legal, and social implications of psychedelics research, commerce, and therapeutics. While psychedelic therapies make their way through the drug development pipeline, seven U.S.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. In conclusion, cannabidiol is associated with clinical improvement in Dravet syndrome. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

SEPTEMBER 12, 2022

This yield gives us the capacity and scale we need to advance our analytical schedule while also developing our product pipeline,” he added. Optimi will also be using the mushrooms to further develop its on-site extraction methods and will use the product to finalize its naturally derived psilocybin offerings this fall. Penis Envy.

History 52

History Clinical Trials Legalization Research and Development 52

The Cannigma

FEBRUARY 2, 2021

In light of these results, the researchers behind the survey say that physicians should pay special consideration to these aspects when advising patients on their medical cannabis treatment options. Patients can also access CBD products without a prescription through local pharmacies. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

SpeedWeed

JULY 6, 2021

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release. Right now, there are a handful of psychedelics research centers at universities around the country.

Policy 52

Policy Law Research and Development Therapy 52

Cannabis Law Report

JULY 28, 2021

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. MAPS PBC strives to continually improve upon the supportive, equitable and accessible work environment.

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. Additionally, they may help slow the growth of certain types of cancer cells, though further research is needed.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. It will continue to engage with medical associations and patients to build evidence, using trials in the UK to accelerate our understanding of how medicinal cannabis can benefit patients.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

NOVEMBER 16, 2021

For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

The Cannigma

DECEMBER 12, 2022

Now, psychedelic research is booming. And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. 19 20 21 22 23.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level.

Law 105

Law Therapy Clinical Trials Research and Development 105

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. The research we completed is exploratory but the results are consistent with our earlier research. “The We look forward to the next chapters in their development”. federal law.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Work with U.S.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JUNE 1, 2021

Steve Barbera to Vice President, Market Access. Drake is well-known as an inspiring and inclusive leader who is dedicated to the development of her teams and solely focused on organizational success for the benefit of patients. Julie Hoff to Vice President, Human Resources. Prior to joining Sesen Bio, Dr. McLin was Sr.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

TheAnswerPage

JANUARY 11, 2022

Thus, an educational gap developed, creating a less than ideal situation for medical marijuana patients. So, why did this educational gap develop? Available at: [link] Accessed 05 Dec. link] -Accessed December 5, 2021. Unfortunately, this did not occur. Le-Short C., Narouze S.N. In: Narouze S.N. Springer, Cham.

Patients 98

Patients Education Marijuana Therapy 98

The Cannigma

JUNE 15, 2021

Both THC and CBD were first isolated in a laboratory in the early 1940s by American researcher Roger Adams. It wasn’t until the 1960s, however, that Israeli researcher Raphael Mechoulam properly identified the chemical structure of CBD, which led to the wealth of knowledge and scope of research we have today. Shutterstock).

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

SEPTEMBER 24, 2019

The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. Nabilone is a medicine, taken as a capsule, that has been developed to act in a similar way to THC. What about other medical cannabis products? There are many different medical cannabis products.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Canna Law Blog

NOVEMBER 6, 2021

Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. But only if it is made affordable and accessible.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

OCTOBER 26, 2019

ii Non-clinical studiesAlthough the use of animals in research is separately regulated by each state and territory, all require compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes (Animal Code). One such circumstance is a clinical trial. medical practitioner), an organisation (e.g.,

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Cannabis Law Report

JANUARY 26, 2022

MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK. No drug is without risks, so clinical trials have included careful investigation of possible adverse effects.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

CannaMD

MARCH 8, 2021

Luckily, you know you can always count on CannaMD to provide the research you need to fight fire with fire! 1455 – and how YOU can fight back with research-based arguments! 1455 covers three major themes: medical marijuana advertising, THC potency/access to high-THC products, and administrative issues. Florida H.B. 1, line 14].

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

NOVEMBER 24, 2021

Published by The Journal of Cannabis Research. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Background. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Members of Congress voiced support for marijuana/AIDS research.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). That access would be available under the auspices of having a chronic, untreatable mood disorder.

Therapy 90

Therapy Legalization Chronic Pain DEA 90